4111.Two
4111.TWO is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the healthcare sector.
Business. 4111.TWO is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the healthcare sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4111.TWO is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the healthcare sector.
The company maintains a strong liquidity position, with a current ratio of 2.01 and cash and equivalents of TWD 443.9 million, which supports its short-term obligations. Its price-to-book ratio of 1.29 and price-to-tangible-book ratio of 1.29 suggest that the market values the company slightly above its book value, indicating a moderate level of investor confidence. The company's low debt-to-equity ratio of 0.02 reflects a conservative capital structure, with minimal reliance on long-term debt.
In terms of profitability, 4111.TWO reports a return on equity (ROE) of 11.9% and a return on assets (ROA) of 8.5%, both of which are strong indicators of efficient asset utilization and profitability. The company's gross profit margin of 39.5% and operating margin of 14.5% are in line with industry norms, suggesting that it is effectively managing its production and operational costs.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of geographic segmentation may expose the company to regional economic or regulatory risks, though the extent of such exposure is not quantified in the available data.
Looking ahead, the company is projected to maintain a stable growth trajectory, with no significant changes in revenue expected in the next fiscal year. Historical revenue data shows a consistent performance, with no sharp fluctuations that would indicate volatility in the business model.
The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's low dilution potential and conservative capital structure reduce the likelihood of equity dilution in the near term. However, the absence of detailed risk disclosures in the filings means that potential long-term risks, such as regulatory changes or competitive pressures, are not fully quantified.
Recent filings and transcripts do not provide specific details on new product launches, strategic partnerships, or major regulatory developments. The company's financial disclosures are consistent with its historical performance, with no material changes in its business operations or financial position reported in the latest available data.
- 4111.TWO maintains a strong liquidity position with a current ratio of 2.01 and significant cash reserves.
- The company's ROE of 11.9% and ROA of 8.5% indicate efficient use of equity and assets.
- The company's capital structure is conservative, with a low debt-to-equity ratio of 0.02.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The company is projected to maintain stable growth with no significant changes in revenue expected.
- Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 4111.TWO Market data — financials · 2026-05-26